Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Top Page
Acurx Pharmaceuticals
(NASDAQ:ACXP)
Select Model
Select Model
Rating:39Underperform
Price Target:―
Acurx Pharmaceuticals' score reflects the challenges of an early-stage biotech, including lack of revenue and ongoing losses, balanced by strong potential in clinical advancements and regulatory support. Technical indicators suggest weak momentum, and valuation is hindered by financial fundamentals.
Positive Factors
Regulatory Support
Regulatory alignment with FDA and EMA for Phase 3 trials enhances the likelihood of successful approval, crucial for market entry and long-term growth.
Clinical Advancements
The successful Phase 2 results with no recurrence bolster the drug's potential, supporting its progress towards commercialization and addressing antibiotic resistance.
Patent Expansion
The new patent strengthens Acurx's intellectual property portfolio, potentially opening new markets and applications, enhancing competitive positioning.
Negative Factors
Cash Position Decline
The declining cash reserves highlight financial strain, potentially limiting operational flexibility and increasing reliance on external funding.
Dependence on External Funding
Reliance on external funding for Phase 3 trials introduces uncertainty, as delays in securing funds could impact development timelines and strategic initiatives.
NASDAQ Listing Risk
Potential delisting from NASDAQ could reduce investor confidence and access to capital markets, affecting the company's financial and strategic options.
Acurx Pharmaceuticals (ACXP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.03M
Dividend YieldN/A
Average Volume (3M)1.14M
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue GrowthN/A
EPS Growth61.10%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.23
Shares Outstanding2,081,323
10 Day Avg. Volume3,231,033
30 Day Avg. Volume1,135,368
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)22.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.34
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$30.50Price Target Upside602.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Acurx Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
How the Company Makes MoneyAcurx Pharmaceuticals makes money primarily through the development and commercialization of its proprietary antibiotic compounds. As a clinical-stage company, its revenue model includes potential future sales of its lead product candidate, ibezapolstat, once it successfully completes clinical trials and receives regulatory approval. Additionally, Acurx may secure revenue through partnerships, licensing agreements, and collaborations with other pharmaceutical companies for the development and commercialization of its pipeline products. These partnerships could involve upfront payments, milestone payments, and royalties on sales. The company's earnings are also influenced by research grants and funding from governmental or non-governmental organizations interested in combating antibiotic-resistant infections.
Acurx Pharmaceuticals Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 12, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments, such as achieving NASDAQ compliance, patent expansion, and successful presentations, alongside ongoing financial challenges and significant reductions in R&D expenses. The company's improved financial position and strategic scientific advancements were notable, though the net loss and reduced R&D spending highlight areas of concern.Q3-2025 Updates
Positive Updates
NASDAQ Compliance Achieved
Acurx Pharmaceuticals effected a 1-for-20 reverse stock split, regaining compliance with NASDAQ listing rules with a minimum bid price of $1 per share and a stockholder equity threshold of $2.5 million.
Patent Expansion
The Australian Patent Office granted a new patent for DNA polymerase 3C inhibitors, adding to existing patents in the U.S., Israel, Japan, and India, strengthening intellectual property for ACX-375C program.
Successful Presentation at ID Week
Acurx was selected to present at ID Week in Atlanta, showcasing ibezapolstat's microbiome-sparing properties and new colonic microbiome data, indicating a low probability of increasing risk for certain infections.
Publication in Nature Communications
Results from a collaboration with Leiden University Medical Center were published, revealing structural biology research on ibezapolstat, marking an important milestone in scientific collaboration.
Financial Position Improvement
The company ended the quarter with $5.9 million in cash, compared to $3.7 million at the end of 2024, and raised additional funds from warrant exercises and equity line of credit.
Negative Updates
Decrease in R&D Expenses
Research and development expenses decreased significantly, from $1.2 million in Q3 2024 to $0.4 million in Q3 2025, primarily due to reductions in manufacturing and consulting costs.
Net Loss Reduction
The company reported a net loss of $2 million for Q3 2025, a decrease from $2.8 million in Q3 2024, indicating ongoing financial challenges despite improvements.
Company Guidance
During the third quarter of 2025, Acurx Pharmaceuticals provided several key updates regarding its financial performance and strategic activities. The company effected a 1-for-20 reverse stock split and regained compliance with NASDAQ's minimum bid price and stockholder equity requirements. Financially, Acurx ended the quarter with $5.9 million in cash, up from $3.7 million at the end of 2024, and raised an additional $1.7 million through an equity line of credit. Research and development expenses decreased to $0.4 million from $1.2 million in the same quarter the previous year, while general and administrative expenses remained flat at $1.6 million. The company reported a net loss of $2 million, or $1.23 per diluted share, compared to a $2.8 million loss, or $3.45 per share, in the prior year. Additionally, Acurx highlighted progress in its ibezapolstat program, including new patent grants, scientific publications, and presentations at industry conferences, while continuing to seek funding opportunities for a phase three clinical trial.Acurx Pharmaceuticals Financial Statement Overview
Summary
Acurx Pharmaceuticals exhibits characteristics typical of early-stage biotech firms, such as no revenue and ongoing net losses. However, the absence of debt and ability to secure financing are positive aspects, though risks from cash outflows remain.Income Statement
Acurx Pharmaceuticals has consistently reported zero revenue over the years, indicating that it might still be in the development phase typical for many biotech companies. The company has incurred significant net losses, which is expected given the lack of revenue and high costs associated with R&D in this industry. However, the absence of revenue sources is a key concern.10
Very Negative
Balance Sheet
The company's balance sheet shows no debt, which indicates conservative financial management and lowers financial risk. However, the low equity ratio and consistent equity erosion due to net losses are concerning. The company has managed to maintain a positive equity position, though it has decreased over the years.35
Negative
Cash Flow
Acurx Pharmaceuticals is experiencing negative operating cash flows due to ongoing net losses, common for biotech firms without a marketable product yet. However, they have been able to secure financing to mitigate cash outflows, which is crucial for their operations. The lack of free cash flow growth is a significant downside.25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.26M | 0.00 | -14.58M | -12.09M | -12.81M | 0.00 |
| Net Income | -9.17M | -14.10M | -14.58M | -12.09M | -12.75M | -4.60M |
Balance Sheet | ||||||
| Total Assets | 6.11B | 3.86M | 7.71M | 9.38M | 13.25M | 3.22M |
| Cash, Cash Equivalents and Short-Term Investments | 5.91B | 3.71M | 7.47M | 9.11M | 12.96M | 3.18M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.50K |
| Total Liabilities | 2.47B | 3.24M | 3.04M | 2.06M | 843.91K | 522.43K |
| Stockholders Equity | 3.64B | 615.12K | 4.67M | 7.32M | 12.41M | 2.70M |
Cash Flow | ||||||
| Free Cash Flow | -7.85M | -10.38M | -9.80M | -7.54M | -5.01M | -3.35M |
| Operating Cash Flow | -7.85M | -10.38M | -9.80M | -7.54M | -5.01M | -3.35M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 8.00M | 6.62M | 8.16M | 3.70M | 14.80M | 4.04M |
Acurx Pharmaceuticals Technical Analysis
Negative
4.34
Price Trends
5.28
Negative
5.98
Negative
7.78
Negative
Market Momentum
-0.35
Positive
37.86
Neutral
5.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Negative. The current price of 4.34 is below the 20-day moving average (MA) of 5.34, below the 50-day MA of 5.28, and below the 200-day MA of 7.78, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 37.86 is Neutral, neither overbought nor oversold. The STOCH value of 5.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACXP.
Acurx Pharmaceuticals Risk Analysis
Acurx Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. Acurx Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acurx Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $11.81M | ― | -207.73% | ― | 1.70% | -111.67% | |
45 Neutral | $9.67M | -0.19 | -81.97% | ― | -46.88% | 34.83% | |
43 Neutral | $26.09M | ― | -54.50% | ― | 185.71% | 79.03% | |
39 Underperform | $10.03M | -0.45 | -291.07% | ― | ― | 61.10% | |
28 Underperform | $2.77M | ― | -169.59% | ― | ― | 85.35% |
* Healthcare Sector Average
ACXP
Acurx Pharmaceuticals
4.34
-23.46
-84.39%
IBIO
Ibio
1.21
-0.98
-44.75%
WINT
Windtree Therapeutics
0.06
-25.46
-99.76%
BRTX
BioRestorative Therapies
1.24
-0.16
-11.43%
LIXT
Lixte Biotechnology Holdings
4.34
2.85
191.28%
BOLT
Bolt Biotherapeutics
4.62
-6.78
-59.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.